Ketoconazole enantiomer for the treatment of diabetes mellitus

Expert Opinion on Investigational Drugs

Volumn 19, Issue 2, 2010, Pages 185-194

  Arakaki, Richard ^a   Welles, Bernice ^b  

^a UNIVERSITY OF HAWAII   (United States)

^b Hawaii and DiOBex Inc   (United States)

Author keywords

Cortisol inhibition; Ketoconazole enantiomers; Type 2 diabetes

Indexed keywords

ATORVASTATIN; C REACTIVE PROTEIN; GLUCOSE; HYDROCORTISONE; KETOCONAZOLE; LIPID; LOW DENSITY LIPOPROTEIN CHOLESTEROL; METFORMIN; PLACEBO;

ABDOMINAL DISCOMFORT; CLINICAL TRIAL; DIARRHEA; DRUG EFFECT; DRUG EFFICACY; DRUG ERUPTION; DRUG SAFETY; DYSPEPSIA; ENANTIOMER; GLUCOSE BLOOD LEVEL; GYNECOMASTIA; HEADACHE; HUMAN; METABOLIC SYNDROME X; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; REVIEW;

ADRENAL GLANDS; CLINICAL TRIALS, PHASE II AS TOPIC; DIABETES MELLITUS, TYPE 2; HUMANS; HYDROCORTISONE; HYPOGLYCEMIC AGENTS; KETOCONAZOLE; LIVER FUNCTION TESTS; STEREOISOMERISM; TREATMENT OUTCOME;

EID: 74549179686     PISSN: 13543784     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543780903381411     Document Type: Review

References (34)

1. United Kingdom Prospective Diabetes Study (UKPDS) Group. Intensive blood glucose control with sulphonylurea or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes. (UKDPS 33) Lancet 1998;356:837-853
2. Holman RR, Paul SK, Bethel MA, et al. 10-Year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med 2008;359:1577-1589
3. Chalmers, J, Cooper ME. UKPDS and the legacy effect. N Engl J Med 2008;359:1618-1620
4. Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Research Group. Retinopathy and nephropathy in patient with type 1 diabetes four years after a trial of intensive therapy. N Engl J Med 2000;342:381-390
5. Nathan DM, Cleary PA, Backlund JY. Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. N Engl J Med 2005;353:2643-2653
6. The Action to Control Cardiovascular Outcomes and Risk in Diabetes Study Group. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med 2008;358:2545-2559
7. The ADVANCE Collaborative Group. Intensive blood glucose control and vascular outcome in patients with type 2 diabetes. N Engl J Med 2008;58:2560-2572
8. Ferrannini E. Insulin resistance versus insulin deficiency in non-insulin-dependent diabetes mellitus: problems and prospects. Endocr Rev 1998;19(4):477-490
9. Friedman TC, Mastorakos G, Newman TD, et al. Carbohydrate and lipid metabolism in endogenous hypercortisolism: shared features with metabolic syndrome X and NIDDM. Endocr J 1996;43(6):645-655
10. Walker BR. Cortisol-cause and cure for metabolic syndrome? Diabet Med 2006;23:1281-1288
11. Andrews R, Phillips DIW, Walker BR. Obesity and gender influence cortisol secretion and metabolism in man. J Clin Endocrinol Metab 1998;83:1806-1809
12. Marinello B, Ronconi V, Rilli S, et al. Adipose tissue 11b-hydroxysteroid dehydrogenase type 1 expression in obesity and cushing's syndrome. Eur J Endocrinol 2005;155:435-441
13. Stulnig TM, Waldhausl W. 11b-hydroxysteroid dehydrogenase type 1 in obesity and type 2 diabetes. Diabetologia 2004;47:1-11
14. Tomlinson JW, Stewart PM. Modulation of glucocorticoid action and the treatment of type-2 diabetes. Best Pract Res Clin Endocrinol Metab 2007;21(4):607-619
15. Hughes KA, Webster SP, Walker BR. 11-Beta-hydroxysteroid dehydrogenase type 1 (11beta-HSD1) inhibitors in type 2 diabetes and obesity. Expert Opin Investig Drugs 2008;17(4):481-496
16. Morton NM, Holms MC, Fievet C, et al. Improved lipid and lipoprotein profile, hepatic insulin sensitivity, and glucose tolerance in 11b-hydroxysteroid dehydrogenase type 1 null mice. J. Biol Chem 2001;276:41293-41300
17. Masuzaki H, Paterson J, Shinyama H, et al. A transgenic model of visceral obesity and the metabolic syndrome. Science 2001;194:2166-2170
18. Paulmyer-Lacroix O, Boullu S, Oliver C, et al. Expression of the mRNA coding for 11b-hydroxysteroid dehydrogenase type 1 in adipose tissue from obese patients: an in situ hybridization study. J Clin Endocrinol Metab 2002;87:2701-2705
19. Kerstens MN, Riemens SC, Sluiter WJ. Lack of relationships between 11beta-hydroxysterod dehydrogenase set point and insulin sensitivity in the basal state and after 24h insulin infusion in healthy subjects and type 2 diabetic patients. Clin Endocrinol (Oxf) 2000;52:403-411
20. Andrews RC, Rooyackers O, Walker BR. Effects of the 11b-hydroxysteroid dehydrogenase inhibitor carbenoxolone on insulin sensitivity in men with type 2 diabetes. J Clin Endocrinol Metab 2003;88:285-291
21. Liu, JK, Fleseriu M, Delashaw JB, et al. Treatment options for cushings disease after unsuccessful transsphenoidal hypophysectomy. Neurosurg Focus 2007;23(3):E8-15
22. Sonino N, Boscaro M, Paoletta A. Ketoconazole treatment in cushing's syndrome: experience in 34 patients. Clin Endocrinol (Oxf) 1991;35:347-352
23. Fallo F, Paoletta A, Tona F, et al. Response of hypertension to conventional antihypertensive treatment and/or steroidogenesis inhibitors in cushing's syndrome. J Inter Med 1993;234:595-598
24. Dunmire D, Freedman TB, Hafie LA, et al. Determination of the absolute configuration and solution conformation of the antifungal agents ketoconazole, itraconazole, and miconazole with vibrational circular dichroism. Chirality 2005;17:S101-8
25. Dilmaghanian S, Gerber JG, Filler SG, et al. Enantioselectivity of inhibition of cytochrome P450 3A4 (CYP3A4) by ketoconazole: testosterone and methadone as substrates. Chirality 2004;16:79-85
26. Rotstein DM, Kertesz DJ, Walker KA, Swinney DC. Stereoisomers of ketoconazole: Preparation and biological activity. J Med Chem 1992;35:2818-2825
27. Diederich S, Grossmann C, Hanke B, et al. In the search for specific inhibitors of human 11b-hydroxysteroid-dehydrogenase (11b-HSDs): chenodeoxycholic acid selectively inhibits 11b-HSD-1. Eur J Endocrinol 2000;142:2007
28. Boudriau S, Demnati R, Swearingen D, et al. Differential effects of co-administration of racemic ketoconazole and levdexketoconazole on the pharmacokinetic profile of atorvastatin. Clin Pharmacol Ther 2008;83(1):S88
29. Park J-Y, Kim K-A, Shin J-C, Lee KY. Effect of ketoconazole on the pharmacokinetics of rosiglitazone in healthy subjects. Br J Clin Pharmacol 2004;58(4):397-402
30. Schwartz SL, Rendell M, Ahmann AJ, et al. Safety profile and metabolic effects of 14 days of treatment with DIO-902: results of a phase IIa multicenter, randomized, double-blind, placebo-controlled, parallel-group trial in patients with type 2 diabetes mellitus. Clin Ther 2008;30:1081-1088
31. Defronzo RA, Ratner RE, Han J, et al. Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes. Diabetes Care 2005;28(5):1092-1100
32. Peyrot M, Rubin RR, Lauritzen T. Resistance to insulin therapy among patients and providers: results of the cross-national Diabetes Attitudes, Wishes, and Needs (DAWN) study. Diabetes Care 2005;28:2673-2679 (Pubitemid 43951158)
33. Nathan DM, Buse JB, Davidson MJ, et al. Medical management of hyperglycemia in type 2 diabetes: A consensus algorithm for the initiation and adjustment of therapy. Diabetes Care 2008;31:1-11
34. Rosenstock J, Banarer S, Fonseca V, et al. Efficacy and safety of the 11-b-HSD1 inhibitor, INCB13739, added to metformin therapy in patients with type 2 diabetes. Diabetes 2009;58(Suppl 1):7-LB, LB3